As you will be aware, the Department for Health and Social Care has asked NICE to undertake an appraisal of blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia.
Please note that following on from advice received from the company, the timelines for this appraisal remain to be confirmed, whilst regulatory timings are established.
NICE will continue to monitor any development and will update interested parties as and when the situation changes.